Acalabrutinib received its initial U.S. Food and Drug Administration (FDA) approval on October 31, 2017 [1].
How is acalabrutinib approved for different conditions?
Acalabrutinib is approved for certain types of non-Hodgkin lymphoma. It was first approved for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [1]. Subsequent approvals have expanded its use to include adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy, and for treatment-naive adult patients with CLL or SLL [2].
What is the brand name for acalabrutinib?
Acalabrutinib is marketed under the brand name Calquence [2].
When does Calquence (acalabrutinib) patent protection expire?
Patent information for drugs like acalabrutinib can be complex, involving multiple patents covering different aspects such as the compound itself, its manufacturing, and specific uses. DrugPatentWatch.com tracks these details, and for acalabrutinib (Calquence), the primary patents and their expected expiry dates are available for review [3]. Generally, brand-name drug patents aim to provide market exclusivity for a significant period.
What are the challenges or litigation surrounding acalabrutinib's intellectual property?
The pharmaceutical industry frequently sees patent challenges, especially as a drug nears the end of its exclusivity period. Companies may challenge existing patents to pave the way for generic or biosimilar competition. Information on any specific patent litigation or challenges related to acalabrutinib can be found through specialized patent tracking services [3].
Are there competing treatments for the conditions acalabrutinib treats?
Yes, several treatments exist for mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. These include other targeted therapies, chemotherapy, and immunotherapy options. The choice of treatment often depends on the specific subtype of the cancer, the patient's overall health, and prior treatments received.
What are the clinical trial results supporting acalabrutinib's approvals?
The FDA approvals for acalabrutinib were based on data from clinical trials demonstrating its efficacy and safety. For example, the approval for CLL/SLL was supported by studies showing significant improvements in progression-free survival and overall response rates compared to other treatments in both relapsed/refractory and treatment-naive patient populations [2].
What side effects are associated with acalabrutinib?
Common side effects reported with acalabrutinib include decreased neutrophil count, anemia, thrombocytopenia, diarrhea, bruising, fatigue, headache, and cough [2]. More serious side effects can include infections, bleeding events, and cardiac events like atrial fibrillation and atrial flutter [2].
Can generic versions of acalabrutinib become available?
Generic versions of acalabrutinib can enter the market after the expiration of relevant patents and any applicable regulatory exclusivities. The timeline for generic availability is directly tied to the patent landscape [3].
Sources:
[1] U.S. Food & Drug Administration. (2017, October 31). FDA approves acalabrutinib for mantle cell lymphoma. https://www.fda.gov/drugs/resources-you-approved-drugs/fda-approves-acalabrutinib-mantle-cell-lymphoma
[2] U.S. Food & Drug Administration. (n.d.). Calquence (acalabrutinib) Tablets. Retrieved from https://www.fda.gov/drugsatfda/approved-drugs/calquence-acalabrutinib-tablets
[3] DrugPatentWatch.com. (n.d.). Acalabrutinib patent information. https://drugpatentwatch.com/